Essential thrombocythemia: challenges in clinical practice and future prospects

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Essential thrombocythemia (ET) is a myeloproliferative neoplasm with evolving understanding of its molecular drivers.
• Despite advances, no new therapies for ET have been approved in over a decade.
• Patient-reported symptoms like fatigue significantly impact quality of life in ET.

Approach:

• This review provides a practical overview of current diagnostic criteria and management strategies for ET.
• It addresses challenging patient scenarios and discusses the components of comprehensive care.
• The review also examines novel therapeutic approaches and their potential evaluation.

Key Points:

• Understanding ET heterogeneity, driven by specific mutations, is crucial for risk assessment and treatment selection.
• Patient-reported symptoms, such as fatigue, are increasingly recognized as important factors in managing ET.
• Current management focuses on preventing vascular events and controlling platelet counts, with evolving therapeutic options.

Conclusions:

• Current ET management requires a nuanced approach considering molecular profiles and patient symptoms.
• Comprehensive care for ET should integrate symptom management and evolving therapeutic strategies.
• Further research and clinical trials are needed to evaluate novel ET therapies.